BiOptic Inc. (6850) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of BiOptic Inc. stock TWD 25.96, price TWD 28.30, that is 8.3% below the price, quality 48 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 25.51 TWD – 52.03 TWD · fair‑value band 18.94 TWD – 37.68 TWD · the 28.30 TWD price screens above the 25.96 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow BiOptic in your weekly email
Every Wednesday you see whether BiOptic is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BiOptic Inc., a biotechnology instrumentation company, develops scientific products for research and clinical applications.
Show moreShow less
It offers instruments, such as bio-fragment analyzers and PCR thermocyclers; consumables, including DNA, RNA, and protein cartridges, as well as quantification kits; premix and polymerase PCR reagents; and veterinary, human, and food related testing kits.
BiOptic Inc.was founded in 1993 and is headquartered in New Taipei City, Taiwan.
Stock analysis
BiOptic Inc. (6850) currently trades at 28.30 TWD, while our model-based Fair Value estimate is 25.96 TWD, so the stock looks roughly fairly valued today (gap 9.0%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 14.08 TWD per share, and 1 of the 26 models we run sit above the 28.30 TWD price.
Bear case: the Asset-Based group reads lowest at 4.57 TWD, and 25 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 18.94 TWD (bear) to 37.68 TWD (bull), the price of 28.30 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BiOptic Inc. reported revenue of 203M TWD in FY2024 versus 124M TWD in FY2020, a compound +13.2%/yr. Reported net income was 22.7M TWD in FY2024, compounding −3.2%/yr from FY2020.
Key figures
Market cap 936M TWD (≈ $28.5M) Micro · P/E ratio 104.8 · P/S ratio 11.8 · EPS (TTM) 0.2700 TWD · Net margin 11.2% · Return on assets (EBIT) 8.5% (5-year average) · Free cash flow 24.3M TWD · Net cash 12.0M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 37% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −8%, 6850 screens richer than that median.
Fair Value models
Bear18.94 TWDFair Value 25.96 TWDBull37.68 TWD
Price 28.30 TWD · Downside -8.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2024 figures (about 12 months old). Earnings retained since then (0.2700 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−11.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.1%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.8%
’18
’19
’20
’21
’22
’23
’24
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.2%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 10%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +21.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 8/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Above median
Fair Value upside−8.3% · Above median
Profitability
Return on assets3.8% · Above median
Net margin (12 months)11.2% · Above median
Operating margin (12 months)0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Dividend yield (12 months)0.0% · Bottom 25%
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BiOptic Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6850
Frequently asked questions
Is BiOptic Inc. (6850) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 25.96 TWD versus a price of 28.30 TWD, about 8% lower (fairly valued).
What is the fair value of 6850?
Our model-based fair value for BiOptic Inc. is 25.96 TWD (as of Nov 3, 2026), built from audited fundamentals. The current price: 28.30 TWD.
What is the quality score of 6850?
BiOptic Inc. has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BiOptic Inc. (6850)?
Our model-based price target is the fair value of 25.96 TWD (as of Nov 3, 2026) from 26 valuation models. Cautious scenario 18.94 TWD, optimistic scenario 37.68 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the BiOptic Inc. stock forecast for 2026?
Our models put fair value at 25.96 TWD, about 8% lower versus a price of 28.30 TWD (fairly valued). Cautious scenario 18.94 TWD, optimistic scenario 37.68 TWD. The calculation is refreshed regularly with new filings.
What growth is priced into BiOptic Inc. (6850)?
For today's price to be fair in a discounted-cash-flow model, BiOptic Inc. would have to grow free cash flow by +23.1 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.1 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 6850 use?
Our models discount BiOptic Inc. at 10.3 %: a base by market capitalisation (nano), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BiOptic Inc. that is +23.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has BiOptic Inc. (6850) delivered so far?
Over the past 5 years revenue at BiOptic Inc. grew +17.1 % a year. The price currently implies free-cash-flow growth of +23.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BiOptic Inc. (6850) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into BiOptic Inc. (+23.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BiOptic Inc. (6850)?
The free-cash-flow yield on the price is 2.59 %: that much free cash flow BiOptic Inc. produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BiOptic Inc. (6850)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BiOptic Inc. it is 25.96 TWD per share (as of Nov 3, 2026), against a price of 28.30 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is BiOptic Inc. stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 6850 trades above its calculated fair value: price 28.30 TWD, fair value 25.96 TWD, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6850?
No. The price is what the market pays today (28.30 TWD); the fair value is what the company's own numbers justify (25.96 TWD). For BiOptic Inc. the two are 2.34 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is BiOptic Inc. worth?
The market values BiOptic Inc. at about 936M TWD (market capitalisation, as of Nov 3, 2026). Per share that is 28.30 TWD; our models calculate a fair value of 25.96 TWD per share.
What do the bullish and bearish scenarios say about 6850?
Our models span a range for BiOptic Inc.: cautious scenario 18.94 TWD, base 25.96 TWD, optimistic 37.68 TWD per share (as of Nov 3, 2026, price 28.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6850?
BiOptic Inc. trades at a price-to-earnings ratio of 104.8 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 25.96 TWD is built from several models across several years. Other multiples: P/B 0.1.
How solid is the balance sheet of BiOptic Inc. (6850)?
Balance-sheet figures for BiOptic Inc. (as of Nov 3, 2026): debt of 0.17 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 6850 from its 52-week high?
BiOptic Inc. trades at 28.30 TWD, about 37% below its 52-week high of 44.72 TWD and at the low of 28.30 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 25.96 TWD is for.
Which stocks are comparable to BiOptic Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BiOptic Inc. stock attractive at the current price?
The data as of Nov 3, 2026: price 28.30 TWD, calculated fair value 25.96 TWD (−8%), Quality Score 48/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6850 calculated?
We run BiOptic Inc. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 25.96 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BiOptic Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BiOptic Inc. (6850)?
The closing price on Nov 6, 2026 was 28.30 TWD. Our model-based fair value is 25.96 TWD, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BiOptic Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (18.94 TWD to 37.68 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of BiOptic Inc.
How large is the market capitalisation of BiOptic Inc. (6850)?
The market capitalisation of BiOptic Inc. is 936M TWD (≈ $28.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BiOptic Inc. (6850)?
The price-to-sales ratio of BiOptic Inc. is 11.8 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BiOptic Inc. (6850)?
Earnings per share at BiOptic Inc. are 0.2700 TWD (price ÷ EPS = P/E 104.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BiOptic Inc. (6850)?
The net margin of BiOptic Inc. is 11.2% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of BiOptic Inc. (6850)?
On an EBIT basis the return on assets of BiOptic Inc. is 8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much net cash does BiOptic Inc. (6850) hold?
BiOptic Inc. holds more cash than debt, 12.0M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch BiOptic Inc. in the live analysis
One click puts BiOptic Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026